Provider review
Shed tirzepatide review
What Shed charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
Read on Shed’s own pages on November 20, 2026: ‘starting as low as $239/mo’ (plan length and dose not stated). It scores 55/100 under our written v4.1 scoring guide, #17 of 22 programs scored.
What is distinctive about this programme
Breadth of formulation, at a cost
Shed publishes compounded semaglutide as injectable ($175 on twelve months), microdose ($149), sublingual lozenges ($199) and liquid drops ($229), plus tirzepatide injectable ($245) and microdose ($199), and liquid drops ($229). No other provider in our dataset offers that spread.
The sublingual and drops formats deserve the standard caution: no trial has tested a compounded sublingual or orally dissolving GLP-1, and bioavailability for these formulations is unpublished. They are priced comparably to injectables that do have trial evidence behind the molecule and route.
Pricing increases at higher doses
Shed is one of the few providers in our dataset explicitly reported as increasing price at higher doses. That matters more than the headline figure: a patient starting at $245 on a twelve-month tirzepatide plan should establish what 10 or 15 mg costs before committing, because the advertised rate is the entry rate.
The two-month minimum and the brand markup
Several programmes carry a two-month minimum, which is milder than a twelve-month prepayment but still removes the option of a single trial month.
Shed's brand offerings carry a $125 membership required for brand access. The Wegovy pen at $199 medication becomes $324 all-in, and Zepbound at $349 becomes $474 — against $299 to $449 direct from LillyDirect with no membership at all.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide microdose | $149 | Provider-reported |
| Semaglutide injectable | $175 | Provider-reported |
| Tirzepatide microdose | $199 | Provider-reported |
| Semaglutide sublingual | $199 | Provider-reported |
| Semaglutide sublingual | $229 | Provider-reported |
| Tirzepatide injectable | $245 | Provider-reported |
Where it holds up
- Widest formulation range in our dataset: injectable, microdose, sublingual and drops
- Microdose semaglutide at $149 is competitively priced within its category
- Two-month minimum is less restrictive than the twelve-month prepayments common elsewhere
- Prices for sublingual formats have been reduced substantially from earlier listings
Where it does not
- Pricing increases at higher doses — the advertised rate is the entry rate
- Sublingual and drops formats have no trial evidence at all
- Brand access requires a $125 membership on top of medication
- Brand Zepbound at $474 all-in against $299–$449 direct from the manufacturer
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Escalates with dose or not established |
| Lowest captured figure | $149/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
| Category | Points |
|---|---|
| Pricing transparency | 20 |
| Total annual cost | 20 |
| Clinical oversight | 15 |
| Pharmacy transparency | 15 |
| Support | 10 |
| Regulatory disclosure | 10 |
| Accessibility | 10 |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Shed | prepaid | compounded injectable | not recorded | $245 | not verified | $245 | Commitment tier | Provider-reported | 2026-07-06 |
| Shed | prepaid | compounded microdose | not recorded | $199 | not verified | $199 | Commitment tier | Provider-reported | 2026-07-06 |
| Shed | prepaid | compounded microdose | not recorded | $149 | not verified | $149 | Commitment tier | Provider-reported | 2026-07-06 |
| Shed | prepaid | compounded injectable | not recorded | $175 | not verified | $175 | Commitment tier | Provider-reported | 2026-07-06 |
| Shed | month_to_month | compounded sublingual | not recorded | $199 | not verified | $199 | Recurring | Provider-reported | 2026-07-06 |
| Shed | prepaid | compounded sublingual | not recorded | $229 | not verified | $229 | Commitment tier | Provider-reported | 2026-07-06 |
How this sits against the market
The July 2026 all-provider chart that stood here has been retired. Current first-party prices for 28 compounded tirzepatide programs (read October 15, 2026; NexLife November 20, 2026) are on the price index.
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Pharmacy and fulfilment
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Shed sits against the median for each rubric category, not against a hand-picked competitor.
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | not verified | Not answered Verification pending |
| Clinical oversight and care continuity | 20 pts | not verified | Not answered Verification pending |
| State access and operational reliability | 10 pts | not verified | Not answered Verification pending |
| Cancellation, billing and support transparency | 10 pts | not verified | Not answered Verification pending |
Questions readers actually ask
Is Shed the cheapest option?
Read on its own page on November 20, 2026: ‘starting as low as $239/mo’ (plan length and dose not stated).
Is compounded tirzepatide the same as Zepbound?
Shed scores 55/100 under the written v4.1 scoring guide, #17 of 22 programs scored from pages read November 20–21, 2026. Its weakest category is pharmacy transparency (2 of 15).
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
- GLP-1 Telehealth vs Local Weight-Loss ClinicComparisons
- GLP-1 Data API DocumentationData
Related coverage
- Ro Body Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Why Multi-Dose Vials Create Tirzepatide Dosing Errors
- The Oral GLP-1 Landscape in 2026
- Retatrutide Phase 3 Results: What Changed in July 2026
- Why Compounded GLP-1 Access Differs by State
- Tirzepatide and Diabetes Prevention Over 176 Weeks
- Tirzepatide and Heart Failure With Preserved Ejection Fraction
GLP-1 Tirzepatide Review. “Shed Tirzepatide Review.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/providers/shed/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.